A whole-gut motility drug that enhances esophageal motility and lower esophageal sphincter tension, prevents reflux of gastric contents, and improves esophageal clearance; increases gastric and duodenal contractility and coordination; reduces duodenal and gastric reflux, and improves gastric and duodenal emptying; strengthens intestinal motility and promotes small and large intestine transit; does not increase basal or pentagastrin-induced gastric acid secretion; has almost no effect on plasma prolactin levels.

Nateglinide is an amino acid derivative and an oral antidiabetic drug used to treat patients with type 2 diabetes. Nateglinide binds to the ATP-sensitive K channel receptor on the β cell membrane and closes it, causing cell depolarization, calcium channel opening, calcium influx, stimulating insulin secretion, and lowering blood sugar. Nateglinide's insulin secretion-promoting effect depends on glucose levels. When glucose levels are low, insulin secretion is weakened. Nateglinide has a high degree of tissue selectivity and has low affinity for cardiac and skeletal muscles.